Biogen Inc. Initiates Phase 3 Pediatric Study of Omaveloxolone for Friedreich Ataxia
Biogen Inc., a healthcare biotechnology company, has initiated a Phase 3 pediatric study of omaveloxolone for the treatment of Friedreich ataxia. The global study, known as the BRAVE study, aims to evaluate the efficacy and safety of omaveloxolone in children aged 2 to less than 16 years old with the rare neurodegenerative disorder.
The study addresses a critical unmet need, as there are currently no approved treatments for pediatric patients with Friedreich ataxia. The expansion of the treatment to this age group is a key development in the company’s efforts to address this rare disease.
Study Details
- Study name: BRAVE study
- Study type: Phase 3 pediatric study
- Age group: Children aged 2 to less than 16 years old
- Disease indication: Friedreich ataxia
Company Stock Price
Biogen Inc.’s stock price has experienced a decline following the announcement, although specific details regarding the price movement are not provided.